Are PARP Inhibitors Ready for Prime Time in Metastatic Prostate Cancer? Maybe Not.
expert_opinion · Level V
Where this comes from
- Record sourced from PubMed, PMID 37244815.
- Also identified by DOI 10.1016/j.eururo.2023.05.017.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
While PARP inhibitors such as rucaparib and olaparib have shown activity in metastatic castration-resistant prostate cancer, they have failed to show a clear improvement in hard outcomes such as overall survival or quality of life. Because of methodological limitations, we suggest caution before implementing these treatments in routine clinical practice; offering them to patients without a BRCA1/2 mutation is probably inappropriate.
Medical subject headings
- Poly(ADP-ribose) Polymerase Inhibitors
- Prostatic Neoplasms, Castration-Resistant